Smartphone Application to PREDICT Real-Time Cardiovascular Risk for Heart Attack and Stroke
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-79
SponsorStanford University
About this trial
To assess the diagnostic accuracy of a smartphone application in predicting heart attack or stroke within 3-4 days in high-risk patients.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Be able to provide electronic or written informed consent and be able to effectively communicate and understand the study procedures, risks, and required activities.
Age 40 to 79 years.
Be willing to wear a smartwatch continuously for 18 months and comfortable with using wearable devices or other technologies that monitor their data over time.
A first degree relative with history of premature ASCVD (males, age <55 years; females, age <65 years).
Disqualifiers
The 10-year ASCVD risk <7.5%.
Elevated troponin at baseline.
Cognitive impairment.
Neurological disorders that would impair their ability to provide informed consent or adhere to study protocols.
Trial design
Design model
Single group
Treatments tested in this trial
Smartphone application Antshrike
DeviceAll participants will wear a smart watch that has an application Antshrike, which will collect demographic data, health history, lifestyle factors, and biobehavioral data for 18 months.
Treatment groups
300 Participants
are divided into 1 treatment groupGroup A: Smartphone application AntshrikeOther 1 intervention
Trial outcomes
Primary outcomes
1
Number of ASCVD events
ASCVD events include myocardial infarction (MI), ischemic stroke/transient ischemic attack (TIA), CV death, or clinically driven arterial revascularization or hospitalization.
Time frame
Baseline through 18 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Stanford University
Lead sponsor
Before Health Intelligence Ltd
Collaborator
Samsung Electronics Co., Ltd
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: